Lakewood-Amedex Registers 4.5M Additional Shares for Series C Holder Resale
LABT sits 17% above its 52-week low of $1.66 on light trading volume (0.2× avg).
Summary
Lakewood-Amedex filed an S-1 to register 4,512,400 additional shares for resale by its Series C Preferred holder, Shakawe Capital LLC, after the reverse split increased the maximum conversion amount at the $1.00 floor price.
Key Events · Financing and Capital Events · LABT
-
4.5M Additional Shares Registered for Resale
The S-1 registers 4,512,400 shares of common stock for resale by Shakawe Capital LLC, the holder of the remaining 451,240 Series C Preferred shares.
-
Reverse Split Inflated Conversion Overhang
The 1:10 reverse split did not adjust the $1.00 conversion floor, increasing the maximum common shares issuable from 937,500 to 4,512,400 for the remaining preferred stock.
-
No Proceeds to Company
Lakewood-Amedex will receive no proceeds from any sales by the selling stockholder; all proceeds go to Shakawe Capital LLC.
-
Prior Conversions Exhausted First Registration
486,260 Series C shares have already converted into 937,500 common shares, fully using the prior S-1 registration, leaving this new filing as the only path for the remaining overhang.
Analysis · LABT · Life Sciences
The 1:10 reverse split in June 2026 did not adjust the $1.00 conversion floor on the Series C Preferred Stock, which mechanically increased the maximum number of common shares issuable upon conversion. This S-1 registers an additional 4,512,400 shares for resale by Shakawe Capital LLC — nearly double the 2,369,688 shares currently outstanding. The company receives no proceeds from these sales, and the holder can sell at market prices from time to time, creating a significant overhang on the stock. Combined with the company's going-concern warning and the pending shareholder vote on an 8x authorized share increase, this filing quantifies a dilution path that existing holders must absorb.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LABT was trading at $1.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $1.66 to $98.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.